Abstract: Compositions and methods to avoid the gag reflex to enable swallowing of pills, by applying an edible coating to the pill that generates bubbles, so that the bubbles prevent direct contact of the pill with the back of the mouth, thereby avoiding the gag reflex. Preferably the coating generates bubbles from an acid-base reaction, from compressed bubbles entrapped in hard candy, or from any other manner for creating fizzing, effervescent or popping confectionary or other food products. Optionally the coating can have a strong taste, such as by being sour, to distract away from the gag reflex. Optionally, a time release envelope is provided to delay bubbling or to block atmospheric humidity.

Abstract: Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. Some of the hyaluronic acid-based compositions can include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. Compared to conventional compositions that include lidocaine, some of the hyaluronic acid-based compositions disclosed herein can have an enhanced stability, for example, when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such compositions are also provided.

Abstract: The present invention relates to a nanocomposite ocular device that can release drugs within a close distance to the ocular surface and provide controlled and sustained release of the drug at a constant rate. The device can achieve both optical and medical functions. The device comprises a drug, one or more reservoir domains, and a barrier layer configured to block the drug diffusion paths from the reservoir domain to the ocular surface in the eye of the subject, wherein the drug partitions between the reservoir domain and the barrier layer, and the equilibrium drug solubility in the reservoir domain is at least five folds higher than that in the barrier layer.

Abstract: An environmentally responsive Paecilomyces lilacinus microbead and its preparation method and application are provided. The Paecilomyces lilacinus microbead includes a capsule core and a capsule wall; wherein, in the capsule core, Paecilomyces lilacinus spore powder, a vegetable oil, glucose, peptone, a cellulose nanofiber, sodium citrate, and a surfactant are combined to form an emulsifiable capsule core; and in the capsule wall, chitosan, gelatin, polyvinyl alcohol, glycerol, and water are combined to form a water-responsive shell. The environmentally responsive Paecilomyces lilacinus microbeads can stimulate the dissolution of polyvinyl alcohol in the shell according to the moisture content in the soil, so that the water in the soil flows into the microbeads. The cellulose nanofibers in the microbeads absorb water and expand, blocking the holes in the shell, resulting in the inability of spores to flow out.

Abstract: The present invention relates to methods for controlling or preventing infestation of soybean by phytopathogenic microorganisms, in particular of the Fusarium genus, Sclerotinia sclerotiorum, Microsphaera diffusa, Septoria glycines and Cercospora sojina, more particularly Fusarium virguliforme, Fusarium solani, Fusarium oxysporum, Fusarium acuminatum, Fusarium chlamydosporum, Fusarium compactum, Fusarium culmorum, Fusarium equiseti, Fusarium graminearum, Fusarium merismoides, Fusarium proliferatum, Fusarium pseudograminearum, Fusarium semitectum, Fusarium subglutinans and Fusarium verticilliodes, comprising applying to a crop of plants, the locus thereof, or propagation material thereof, a compound according to formula (I), wherein R1, R2, R3, R4, R5, Y, A, B are as defined herein.

Abstract: Provided herein are compositions, systems, kits, and methods for treating a viral, bacterial, protozoan, and/or fungal (e.g., onychomycosis and/or Tinea pedis) infection.

Abstract: Disclosed herein are compositions of rAAV particles and methods for administrating rAAV particles having enhanced transduction properties.

Abstract: Methods, compositions and systems are presented to deliver estradiol benzoate to an animal so as to sterilize the animal. A physiologically acceptable oil or other carrier in a capsule is used to deliver the estradiol benzoate. The estradiol benzoate is delivered intraperitoneally, intramuscularly, or subcutaneously to a companion or livestock animal.

Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.

Abstract: A system for facial remodeling, including a device and methods of use, is provided. The system combines a topical composition configured to restore elastin, hyaluronan, or both to the skin and subcutaneous soft tissues of the face and neck with a facial mask to support and, in some embodiment, compress the tissue, to enhance and preserve the tissue remodeling effects of the composition. Some versions of the facial mask device include a means for electrically grounding the skin and soft tissues of the face, neck, and head, wherein the user receives local tissue benefits of “earthing.” In some versions, the facial mask is formed by combining different elements and configurations to compress skin and underlying soft tissue, bias areas of skin and soft tissue in a cranial direction, and ground the face, head, and neck tissues.

Abstract: The present invention relates to a composition comprising microcapsules, which comprise a polyurea shell and a core, wherein the core comprises pendimethalin and the shell comprises a polymerization product of a tetramethylxylylene diisocyanate, and a polyamine with at least three amine groups, and where the polymerization product comprises less than 5 wt % of further isocyanate monomers in polymerized form, based on the weight of the tetramethylxylylene diisocyanate; a method for preparing the composition comprising the steps of contacting water, the pendimethalin, the tetramethylxylylene diisocyanate, and the polyamine; and to a method of controlling undesired plant growth, wherein the composition is allowed to act on the soil and/or on undesired plants and/or on the crop plants and/or on their environment.

Abstract: Embodiments of a finishing powder of this disclosure include a rice powder and an iron-oxide pigment, with no talc or parabens, that eliminates transfer of wet or sticky spray tan bronzer to clothing, hands, or between opposing folds or creases of skin. The finishing powder may be applied full body—for example 85% to 95% of total body surface area—by way of a brush, being too thick in its consistency to spray. The powder may be blown from the brush to the body. An amount of the mixture applied to a user may be in a range ¾ teaspoon to 2¼ teaspoon. The powder immediately coats the spray tanning solution and remains dry to the touch. Because of its thicker consistency, the powder does not dissipate and remains on the skin up to 24 hours or until the user showers.

Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.

Abstract: Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone.

Abstract: The invention relates to a kit to prepare an hemostatic flowable comprising: —A hemostatic powder having a composition comprising: ?non-cross-linked collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen; ?at least one monosaccharide; and ?at least one glycosaminoglycan; —A saline solution to be mixed with the hemostatic powder in order to form the hemostatic flowable. The invention also relates to a method for preparing an hemostatic flowable with such a kit, comprising the steps of: a. Providing the hemostatic powder in a container; b. Adding a quantity of the saline solution in the container enclosing the hemostatic powder, closing and shaking said container in order to promote hydration of the hemostatic powder to form the hemostatic flowable.

Abstract: The invention relates to an avocado extract rich in polyphenols, containing at least 10% by weight of polyphenols, expressed in gallic acid equivalent relative to the dry extract obtained, wherein said polyphenols contain procyanidins, cafeic acid and cafeic acid derivatives, typically in a proportion of at least 70% by weight, expressed in gallic acid equivalent relative to the total polyphenol content by weight. The invention also relates to a composition comprising an extract according to the invention as active agent and a suitable excipient. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths.

Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Abstract: This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).

Abstract: The present disclosure relates to compositions, including, hydrogel compositions useful as topical analgesics including cannabinoids and anesthetics. The present disclosure also disclosure relates to compositions, including, hydrogel compositions useful as topical analgesics including cannabinoids and anesthetic as well as carboxymethyl cellulose, carrageenan and a cross-linking agent.

Abstract: A composition and method for rapidly inducing a state of endogenous ketosis, the composition including: about 26.66-28.57 percent by mass of alpha lipoic acid; about 0.01-0.02 percent by mass of chromium picolinate; about 47.61-49.99 percent by mass of L-arginine; and, about 23.33-23.81 percent by mass of calcium carbonate. The method includes restricting carbohydrate consumption to a maximum dosage of about 20 grams prior to consumption of the composition and wherein consumption of the composition is on an empty stomach. About thirty minutes after consumption of the composition the user performs moderate intensity exercise. About three hours after consuming a first dose the user tests for a presence of ketones in urine utilizing at least one sodium nitroprusside urine ketone reagent strip.